Mouse Anti-Human CD110 Antibody (S-3014)

CD110, also known as thrombopoietin receptor (TPOR) or MPL (myeloproliferative leukemia protein), is a 635-amino-acid, single-pass type I transmembrane glycoprotein belonging to the hematopoietic cytokine receptor superfamily, whose extracellular N-terminal region binds thrombopoietin (TPO) with high affinity to activate JAK2/STAT, MAPK and PI3K-AKT signaling cascades that drive megakaryocyte proliferation, differentiation and platelet production, while its cytoplasmic C-terminal tail contains critical motifs for internalization and negative feedback regulation; physiologically expressed on hematopoietic stem cells, megakaryocytes, platelets and endothelial cells, CD110 is essential for steady-state and stress hematopoiesis, and genetic alterations—such as MPL W515L/K activating mutations or CALR exon 9 mutations that create neomorphic ligand binding—lead to ligand-independent signaling, constitutive activation and the development of myeloproliferative neoplasms, making CD110 a key diagnostic marker and therapeutic target for small-molecule JAK inhibitors and TPO receptor agonists/antagonists in thrombocytopenias and myelofibrosis.